Cellectis SA (CLLS)vsRevolution Medicines Inc (RVMD)
CLLS
Cellectis SA
$1.17
-7.14%
HEALTHCARE · Cap: $93.23M
RVMD
Revolution Medicines Inc
$190.27
+0.82%
HEALTHCARE · Cap: $38.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Cellectis SA generates 8501% more annual revenue ($63.82M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -102.3%. RVMD earns a higher WallStSmart Score of 24/100 (F).
CLLS
Avoid21
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.3%
Fair Value
$28.65
Current Price
$1.17
$27.48 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -112.3% — below average capital efficiency
Trading at 15.6x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CLLS
The strongest argument for CLLS centers on Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CLLS
The primary concerns for CLLS are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.06 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
CLLS profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.
CLLS carries more volatility with a beta of 2.91 — expect wider price swings.
CLLS is growing revenue faster at -62.1% — sustainability is the question.
CLLS generates stronger free cash flow (-15M), providing more financial flexibility.
Bottom Line
RVMD scores higher overall (24/100 vs 21/100). CLLS offers better value entry with a 87.3% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cellectis SA
HEALTHCARE · BIOTECHNOLOGY · USA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?